Biological
Motavizumab clinical trials
Also written MEDI-524.
- studies test it
- 11
- open now
- 0
- in phase 3
- 3
- first study started
- 2003
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2004 (4)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 5
- Phase 3
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses motavizumab is read from its arms, and is right about nine times in ten.
Testing it · 11
- MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United StatesCompletedPhase 3MedImmune LLCNCT00121108Written as Motavizumab
- Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV InfectionCompletedPhase 1MedImmune LLCNCT00192504Written as Motavizumab
- A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) IllnessCompletedNot applicableMedImmune LLCNCT00421304Written as Motavizumab
- A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) IllnessTerminatedPhase 2MedImmune LLCNCT00435227Written as Motavizumab
- Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk ChildrenCompletedPhase 3MedImmune LLCNCT00129766Written as motavizumab (MEDI-524)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in ChildrenCompletedPhase 1/2MedImmune LLCNCT00113490Written as motavizumab (MEDI-524)
- Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) SeasonCompletedPhase 2MedImmune LLCNCT00316264Written as Motavizumab, palivizumab
- A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in InfantsWithdrawnPhase 3MedImmune LLCNCT00628303Written as Motavizumab
- A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart DiseaseCompletedPhase 2MedImmune LLCNCT00538785Written as Motavizumab
- Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy AdultsCompletedPhase 1MedImmune LLCNCT00192465Written as MEDI-524 (Numax-TM)
- Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524CompletedPhase 1/2MedImmune LLCNCT00192478Written as Medi-524
Codes
What other systems call motavizumab · ClinicalTrials.gg INT004861
- MeSH (NLM) C506968motavizumabOne source NLM
- UNII (FDA) 50Y163LK8QMOTAVIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q6917147MotavizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88584MotavizumabOne source FDA
- DrugBank DB06310One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C506968 | motavizumab | One source NLM |
| UNII (FDA) | 50Y163LK8Q | MOTAVIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6917147 | Motavizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88584 | Motavizumab | One source FDA |
| DrugBank | DB06310 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.